Literature DB >> 27916166

Recurrence after surgery in esophago-gastric junction adenocarcinoma: Current management and future perspectives.

Alessandro Neri1, Daniele Marrelli1, Costantino Voglino2, Giulio Di Mare1, Francesco Ferrara1, Mario Marini3, Franco Roviello1.   

Abstract

Recurrent esophago-gastric junction adenocarcinoma is not a rare event and its correct management is still debated. Many approaches for the treatment of these patients exist, but only few studies compare the different techniques. Most of the studies are retrospectives series and describe the experiences of single institutions in the treatment of recurrent esophageal and esophago-gastric junction cancers. Nowadays surgery is still the main and only curative treatment. Other alternative palliative therapies could be endoscopic stent placement and balloon dilation, photodynamic therapy, thermal tumor ablation (laser photoablation and Argon plasma coagulation), radiation therapy and brachytherapy, and chemotherapy. The aim of this review is to investigate the different rates, patterns and timings of recurrence of this tumor, and to explain the various approaches used for the treatment of recurrent esophago-gastric junction cancer. Copyright Â
© 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adenocarcinoma; Esophageal cancer; Esophago-gastric junction; Gastric cancer; Palliation; Recurrence

Mesh:

Year:  2016        PMID: 27916166     DOI: 10.1016/j.suronc.2016.08.003

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  2 in total

1.  Follow-up after curative resection for gastric cancer: Is it time to tailor it?

Authors:  Paolo Aurello; Niccolò Petrucciani; Laura Antolino; Diego Giulitti; Francesco D'Angelo; Giovanni Ramacciato
Journal:  World J Gastroenterol       Date:  2017-05-21       Impact factor: 5.742

2.  Routinely staging gastric cancer with 18F-FDG PET-CT detects additional metastases and predicts early recurrence and death after surgery.

Authors:  John M Findlay; Stefan Antonowicz; Ashvina Segaran; Jihene El Kafsi; Alexa Zhang; Kevin M Bradley; Richard S Gillies; Nicholas D Maynard; Mark R Middleton
Journal:  Eur Radiol       Date:  2019-01-14       Impact factor: 5.315

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.